Acadia Pharmaceuticals (ACAD) Operating Margin (2010 - 2026)

Acadia Pharmaceuticals' Operating Margin history runs 17 years deep, the most recent figure standing at 1.72% for Q1 2026.

• In Q1 2026, Operating Margin fell 962.0% year-over-year to 1.72%; the TTM figure through Mar 2026 stood at 7.39% (down 1619.0% YoY), while the FY2025 annual figure was 9.78%, down 1431.0% from the prior year.
• Operating Margin for Q1 2026 stood at 1.72%, down from 6.12% in the prior quarter.
• The five-year high for Operating Margin was 59.13% in Q4 2024, with the low at 97.88% in Q1 2022.
• The 5-year median for Operating Margin is 6.12% (2025), against an average of 6.28%.
• The sharpest annual moves came in 2023 and 2025: Operating Margin surged 5264 bps in 2023, then sank 5301 bps in 2025.
• Acadia Pharmaceuticals' Operating Margin stood at 33.75% in 2022, then jumped by 145 bps to 15.12% in 2023, then surged by 291 bps to 59.13% in 2024, then sank by 90 bps to 6.12% in 2025, then sank by 128 bps to 1.72% in 2026.
• Business Quant data shows ACAD's Operating Margin at 1.72% in Q1 2026, 6.12% in Q4 2025, and 12.83% in Q3 2025.